Meddenovo Drug Design funding news – Lyon-based Meddenovo Drug Design Secures €1 Million in Pre-Seed Funding

Ilke Ugur Marion, co-founder and CEO said, “Our platform is the only one specifically designed to harness the potential of cyclic peptides, Despite their optimal size and ideal pharmaceutical properties, cyclic peptides still remain an untapped potential in drug development. Our mission is to fill this gap, using advanced AI-powered technology to streamline the design and testing of new therapeutics.”

In the end, the company hopes to shorten the time it takes for new medications to reach the market, which will hasten the creation of efficient treatments for illnesses like cancer and autoimmune disorders as well as global health issues like antibiotic resistance.

Read also - Credo AI funding news – Brussels-based Credo AI Secures €19.4 Million in Funding

The founders of Meddenovo are passionate about the company's objective and have a wealth of experience in it. The CEO and co-founder, Dr. Ilk Ugur Marion, has a strong history in project management, scientific research, and medicine development. Co-founder and chief technical officer Dr. Antoine Marion brings extensive experience in design method development and is a computational chemistry code development expert.

Gokhan Guner, Managing Partner at ACT Venture Partners said, "Meddenovo targets pharmaceutical and biotech companies looking to innovate and enhance their drug design processes, With the global therapeutic peptides market projected to continue its strong growth, Meddenovo is well-positioned to capitalise on this trend. The company's scalable solutions, combined with a focus on innovation and efficiency, provide a strong foundation for sustained growth and market leadership.”

The additional funds will broaden Meddenovo's clientele and alliances while quickening research and development and improving its AI-driven platforms. This entails encouraging co-development opportunities and switching from a service-based paradigm to a Software as a Service (SaaS) model.

About Meddenovo

Meddenovo provides a special fusion of molecular modelling and artificial intelligence technologies to boost productivity and success in drug development procedures. Their technology platform, which includes focAlyze and bioAIM, provides unmatched drug candidate potency assessment and drug-like property optimisation.

Apart from developing small organic molecules, we also have expertise in peptide-based medicine and metal chelators that goes beyond conventional limits, giving them a competitive edge when it comes to developing solutions for new drug discovery and development projects.